ECHA Endocrine Disruptors
ECHA Endocrine Disruptors
For REACH substances, inclusion in the list means that an informal hazard assessment for endocrine-disrupting properties either is under development or has been completed since the start of the implementation of the SVHC Roadmap in February 2013.
For each substance, the table shows the assessing or evaluating Member State (submitter), the outcome and the suggested follow-up for the assessment, and the date of the latest update to the list entry.
Other process details and hazard assessment outcome documents are also available and can be accessed through the ‘Details’ icon.
One possible outcome of such an assessment is that a substance is considered not to have ED properties.
If the outcome is that the substance is considered to have ED properties, confirmation through the formal risk management and decision-making processes under REACH/BPR is needed before any regulatory action can be taken due to these properties.
The intentions of authorities to submit a dossier to the formal REACH and CLP processes are notified through the Registry of Intentions. All biocidal active substances have to undergo a formal ED assessment. You can see the status of biocides assessments on the Biocidal Active Substances page.
*Pharos filters out chemicals that are concluded as "not endocrine disruptors" in this list. Pharos includes separate endpoints for endocrine disruption in humans and endocrine disruption in the environment. Assessments for either of these endpoints that are under development, inconclusive, or postponed are included in a single hazard sublist. In addition, in 2023 the European Commission amended the CLP regulation and established new hazard classes and criteria for the classification, labeling and packaging of substances and mixtures. Pharos will include updated hazard classifications for endocrine disruption that are consistent with these new hazard classes after the transitional period for these new hazard classes is complete.